Management of Jaundice During TB Treatment

Immediate Actions

The American Thoracic Society recommends stopping all hepatotoxic TB drugs immediately when jaundice develops, and initiating non-hepatotoxic therapy with streptomycin and ethambutol until liver function normalizes 1, 2
Discontinue rifampicin, isoniazid, and pyrazinamide immediately upon detection of jaundice, regardless of transaminase levels, as bilirubin elevation indicates significant hepatic injury 1, 2
Obtain urgent liver function tests including AST/ALT and bilirubin to assess severity 1, 3
Perform virological testing for hepatitis A, B, C, and E to exclude alternative causes 1, 2
Assess alcohol consumption history, as concurrent use significantly increases hepatotoxicity risk 4, 2

For patients who are unwell or have smear-positive sputum, start streptomycin and ethambutol immediately as bridge therapy until liver function normalizes 1, 2
Ethambutol should be dosed at 15-20 mg/kg daily 2
This combination provides adequate coverage while avoiding hepatotoxic agents 1, 2

Once liver function tests normalize completely, reintroduce drugs sequentially with daily clinical and laboratory monitoring 1, 2
Start isoniazid at 50 mg/day and increase to 300 mg/day after 2-3 days if no reaction occurs 1, 2
Start rifampicin at 75 mg/day and increase to 300 mg after 2-3 days without reaction 1, 2
Start pyrazinamide at 250 mg/day and increase to 1.0 g after 2-3 days 1, 2

Check liver function tests (AST/ALT and bilirubin) daily during each drug reintroduction phase 1, 2
Stop the most recently added drug immediately if any of the following occur: AST/ALT rises above 5 times upper limit of normal, AST/ALT rises above normal range with symptoms of hepatitis, bilirubin rises above normal range, or development of fever, malaise, vomiting, jaundice, or abdominal pain 1, 2, 4, 5

If pyrazinamide is the offending drug, use isoniazid and rifampicin for 9 months total, supplemented with ethambutol for the initial 2 months 1, 2
If isoniazid cannot be tolerated, use rifampicin, ethambutol, and a fluoroquinolone for 12 months 2
If multiple drugs cannot be reintroduced, consult a TB specialist for alternative regimens using second-line agents 1, 2

Late onset of jaundice (>1 month) is likely pyrazinamide-induced hepatitis with poor prognosis 4
Avoid pyrazinamide reintroduction in patients with severe initial hepatotoxicity, particularly if jaundice occurred late in treatment, as recurrence carries poor prognosis 2

Never continue hepatotoxic drugs while "monitoring closely" once jaundice develops—this can lead to fulminant hepatic failure requiring transplantation 1, 2
Do not reintroduce all drugs simultaneously—sequential reintroduction identifies the offending agent 1, 2
Avoid concurrent hepatotoxic medications, including over-the-counter acetaminophen during TB treatment 4, 6
Patients with pre-existing liver disease, chronic alcohol use, or hepatitis B/C require more intensive monitoring with weekly liver function tests for 2 weeks, then biweekly for 2 months 1, 3